Candel Therapeutics, Inc. (CADL) Stock Analysis & Investment Frameworks
Candel Therapeutics, Inc. (CADL) stock analysis on Invetso. Review Candel Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Candel Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Candel Therapeutics, Inc. Key Financial Metrics
- Market Cap: $615.21M
- Revenue: $N/A
- ROE: -89.38%
- ROIC: -36.74%
- Dividend Yield: N/A
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.